Navigation path

Additional tools

  • Print version
  • Decrease text
  • Increase text
  • Choose high contrast version
  • Choose standard colour version




Profile of registrant

F. Hoffmann-La Roche Ltd.

Identification number in the register: 18940431725-51
Registration date: 20/05/09 10:57:35

The information on this organisation was last modified on 02/05/14 11:14:00
The date of the last annual update was 02/05/14 11:14:00


Registrant : Organisation or self-employed individual

Name/company name: F. Hoffmann-La Roche Ltd.
Acronym: Roche
Legal status: Corporation
Website address: http://www.roche.com

Sections

Section: II - In-house lobbyists and trade/professional associations
and more precisely: Companies & groups

Person with legal responsibility

Surname, Name: Mr  Severin Schwan
Position: CEO

Permanent person in charge of EU relations

Surname, Name: Nathalie Stieger
Position: Head of Government Affairs

Contact details:

Contact details of organisation's head office: 124 Grenzacherstrasse 
Basel 4070
SWITZERLAND
Telephone number: (+41) 61 688 11 11
Fax number: (+) 
Other contact information:

Goals / remit

Goals / remit of the organisation: Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
The organisation's fields of interests are:
  • global

Number of persons engaged in activities falling under the scope of the Transparency Register

Number of persons: 7
Complementary information:

Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Sabine Atzor 09/08/13 07/08/14
Nathalie STIEGER 19/06/14 17/06/15

Activities

Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:


- Interactions (direct contacts) with EU Institutions relating to legislation, and implementation of EU regulation at national level;
- Inputting EU Institutions open consultation, including participation in events sponsored by EU Institutions;
- Organisation / sponsoring of information meetings, involving EU Institutions;
- Improve patient safety and strengthen disease prevention in Europe;
- Increase Europe’s competitiveness as a location for Research and Development investment;
- Pharmaceuticals, Diagnostics, Diabetes Care, Intellectual Property, Trade

Fields of interest for e-mail alerts on consultations and roadmaps;

Fields declared by the organisation:
  • Consumer Affairs
  • Development
  • Enterprise
  • Environment
  • Internal Market
  • Public Health
  • Research and Technology
  • Trade

Networking

Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.




Roche is a member of EFPIA, EBE, EDMA, EPPOSI, Kangaroo Group.

Financial data

Financial year: 01/2013 - 12/2013
Estimated costs to the organisation directly related to representing interests to EU institutions in that year: 450000  € - 500000  €
Amount and source of funding received from the EU institutions in financial year n-1 of registration
Procurement: 0 €
Grants: 0 €
Other (financial) information provided by the organisation:

This estimate is based on the EU Lobbying activities undertaken by various experts within the company as Roche does not have an EU Public Affairs office in Brussels.

Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code:
Roche Code of Conduct